Representative Dan Newhouse (R-Washington) recently sold shares of Thermo Fisher Scientific Inc. NYSE: TMO. In a filing disclosed on May 16th, the Representative disclosed that they had sold between $1,001 and $15,000 in Thermo Fisher Scientific stock on April 11th. The trade occurred in the Representative's "EDWARD JONES IRA" account.
Representative Dan Newhouse also recently made the following trade(s):
- Sold $1,001 - $15,000 in shares of PayPal NASDAQ: PYPL on 4/11/2025.
- Sold $1,001 - $15,000 in shares of UnitedHealth Group NYSE: UNH on 4/11/2025.
- Sold $1,001 - $15,000 in shares of Moody's NYSE: MCO on 4/11/2025.
- Sold $1,001 - $15,000 in shares of NVIDIA NASDAQ: NVDA on 4/11/2025.
- Sold $1,001 - $15,000 in shares of Dollar General NYSE: DG on 4/11/2025.
- Sold $1,001 - $15,000 in shares of Lowe's Companies NYSE: LOW on 4/11/2025.
- Sold $1,001 - $15,000 in shares of Intuit NASDAQ: INTU on 4/11/2025.
- Sold $1,001 - $15,000 in shares of Microsoft NASDAQ: MSFT on 4/11/2025.
- Sold $1,001 - $15,000 in shares of BlackRock NYSE: BLK on 4/11/2025.
- Sold $1,001 - $15,000 in shares of Broadcom NASDAQ: AVGO on 4/11/2025.
Thermo Fisher Scientific Stock Performance
Thermo Fisher Scientific stock traded down $1.67 during midday trading on Wednesday, hitting $401.88. The stock had a trading volume of 1,930,021 shares, compared to its average volume of 1,874,739. The company has a market capitalization of $151.71 billion, a PE ratio of 24.31, a P/E/G ratio of 2.99 and a beta of 0.82. Thermo Fisher Scientific Inc. has a 52-week low of $390.50 and a 52-week high of $627.88. The firm's fifty day moving average is $437.74 and its two-hundred day moving average is $502.70. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The company had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.23 billion. During the same quarter in the prior year, the firm posted $5.11 EPS. Thermo Fisher Scientific's quarterly revenue was up .2% compared to the same quarter last year. On average, research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.
Thermo Fisher Scientific Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Friday, June 13th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, June 13th. This represents a $1.72 annualized dividend and a yield of 0.43%. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.09%.
Institutional Trading of Thermo Fisher Scientific
Several institutional investors and hedge funds have recently made changes to their positions in the business. Capital Investment Advisors LLC grew its stake in Thermo Fisher Scientific by 15.4% in the fourth quarter. Capital Investment Advisors LLC now owns 1,335 shares of the medical research company's stock worth $695,000 after purchasing an additional 178 shares in the last quarter. SeaCrest Wealth Management LLC increased its stake in shares of Thermo Fisher Scientific by 26.7% during the fourth quarter. SeaCrest Wealth Management LLC now owns 1,743 shares of the medical research company's stock valued at $907,000 after buying an additional 367 shares during the period. Thurston Springer Miller Herd & Titak Inc. raised its holdings in shares of Thermo Fisher Scientific by 74.7% in the fourth quarter. Thurston Springer Miller Herd & Titak Inc. now owns 166 shares of the medical research company's stock valued at $86,000 after acquiring an additional 71 shares in the last quarter. Pinnacle Bancorp Inc. increased its position in Thermo Fisher Scientific by 18.1% during the 4th quarter. Pinnacle Bancorp Inc. now owns 866 shares of the medical research company's stock valued at $451,000 after purchasing an additional 133 shares during the period. Finally, HCR Wealth Advisors boosted its stake in shares of Thermo Fisher Scientific by 0.7% during the fourth quarter. HCR Wealth Advisors now owns 7,499 shares of the medical research company's stock valued at $3,902,000 after purchasing an additional 54 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors.
Insider Activity at Thermo Fisher Scientific
In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 3,775 shares of the stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the completion of the sale, the senior vice president now directly owns 10,816 shares of the company's stock, valued at approximately $5,759,736.32. This represents a 25.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the sale, the chief executive officer now directly owns 115,174 shares of the company's stock, valued at $59,506,950.58. The trade was a 7.99% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 14,075 shares of company stock valued at $7,305,942 over the last ninety days. 0.33% of the stock is owned by company insiders.
Analysts Set New Price Targets
A number of research analysts recently commented on TMO shares. Wall Street Zen raised Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Wednesday, May 21st. Wells Fargo & Company cut their target price on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating for the company in a research note on Thursday, April 24th. Robert W. Baird decreased their price target on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating on the stock in a research note on Thursday, April 24th. Royal Bank of Canada reduced their target price on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a report on Thursday, April 24th. Finally, Argus dropped their price target on Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating for the company in a research note on Tuesday, April 29th. Four investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company's stock. According to MarketBeat.com, Thermo Fisher Scientific currently has an average rating of "Moderate Buy" and a consensus price target of $607.43.
Read Our Latest Report on TMO
About Representative Newhouse
Dan Newhouse (Republican Party) is a member of the U.S. House, representing Washington's 4th Congressional District. He assumed office on January 3, 2015. His current term ends on January 3, 2027.
Newhouse (Republican Party) ran for re-election to the U.S. House to represent Washington's 4th Congressional District. He won in the general election on November 5, 2024.
Click here to see Newhouse's key votes in Congress.
Newhouse served as a member of the Washington House of Representatives representing District 15-Position 2 from 2003 through 2009 and as Washington Director of Agriculture from 2009 to 2013.
Newhouse was first elected to the state House in 2002 and served until he was named state Director of Agriculture in 2009. He was first appointed by Governor Christine Gregoire on February 18, 2009.
About Thermo Fisher Scientific
(
Get Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Further Reading
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
